ScreenerHero
SPRINTSprint Bioscience AB (publ)
STO · SE · Healthcare · Biotechnology · sprintbioscience.com
3.170SEK+5.32%Mkt Cap: 31.99M $P/E: 3.37

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap31.99M $
Enterprise Value20.02M $
Revenue (TTM)14.66M $
Gross Profit14.74M $
Net Income (TTM)8.77M $
Revenue/Share0.1444 USD
Last Price3.170 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees30
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0006343745
Valuation
P/E (Trailing)3.37
P/E (Forward)2.34
PEG—
EV/EBITDA2.34
EV/Revenue1.37
P/S2.09
P/B3.02
EPS (TTM)0.94
EPS (Forward)1.30
52W Range
0.512065% of range4.590
52W High4.590 SEK
52W Low0.5120 SEK
Profitability
Gross Margin92.18%
Oper. Margin-27098.11%
EBITDA Margin58.39%
Profit Margin54.88%
ROE76.97%
ROA67.13%
Growth
Revenue Growth-99.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF7.99M $
CapEx (TTM)8.99K $
FCF Margin27.47%
FCF Yield12.59%
Net Debt-10.36M $
Net Debt/EBITDA-1.21
Balance Sheet
Debt/Equity—
Current Ratio9.10
Quick Ratio9.10
Book Value/Sh1.007 SEK
Cash/Share1.027 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.800 SEK
Upside (mean)+51.4%
Target Range4.800 SEK – 4.800 SEK
# Analysts1
Ownership
Shares Out.105.52M
Float70.57M
Insiders27.84%
Institutions40.64%
Technical
SMA 503.799 (-16.6%)
SMA 2002.602 (+21.8%)
Beta-0.50
S&P 52W Chg18.16%
Avg Vol (30d)232.09K
Avg Vol (10d)199.38K
Technical Indicators
RSI (14)29.0
MACD-0.1504
MACD Signal-0.1127
MACD Hist.-0.0377
BB Upper3.908 SEK
BB Middle3.502 SEK
BB Lower3.097 SEK
BB Width23.18%
ATR (14)0.2408 SEK
Vol Ratio (20d)7.05x